REPLIMUNE GROUP INC (REPL)       25.89  -0.24 (-0.92%)

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 206 full-time employees. The company went IPO on 2018-07-20. The firm is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The firm's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The firm's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathway activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801

P: 17812229600.0

CEO: Philip Astley-Sparke

Employees: 206

Website: https://www.replimune.com/